Idiopathic Pulmonary Fibrosis

Slide 1 · Idiopathic pulmonary fibrosis

The usual interstitial pneumonia pattern: mechanisms, morphology and clinical consequences

Pathogenesis • Usual interstitial pneumonia • Clinical correlation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Distinguish idiopathic pulmonary fibrosis (IPF) from the histologic pattern usual interstitial pneumonia (UIP).

Explain how epithelial vulnerability, repeated injury and fibroblast activation converge in IPF.

Recognize spatial and temporal heterogeneity, fibroblastic foci and honeycomb fibrosis.

Relate restrictive physiology and clinical progression to the underlying morphologic changes.

Slide 3 · IPF: A progressive fibrosing clinicopathologic syndrome

Progressive interstitial scarring damages gas-exchanging lung and may culminate in respiratory failure.

The disorder is idiopathic: No specific external cause is established for the individual case.

Its diagnosis integrates clinical, radiologic and, when available, pathologic information.

The characteristic histologic pattern is usual interstitial pneumonia (UIP).

Slide 4 · Where IPF fits within restrictive lung disease

Interstitial / parenchymal restriction

Predominantly inflammation and/or fibrosis of interstitium

Reduced lung compliance and lung volumes

IPF is a prototypic fibrosing example

Extraparenchymal restriction

Mechanically limits thoracic expansion

Examples: Obesity, pleural or neuromuscular disorders

Does not require the UIP fibrotic lung pattern

Slide 5 · Physiologic consequences of interstitial fibrosis

Interstitial collagen deposition

Stiff, poorly compliant lung

Reduced lung volumes

Progressive respiratory limitation

Mechanistic sequence linking microscopic scarring with restriction (schematic).

Interpretation is mechanistic and conceptual; Scale and timing are schematic.

Slide 6 · Chronic interstitial lung diseases are heterogeneous

Several fibrosing, granulomatous, smoking-related and other conditions can produce an interstitial syndrome.

Imaging and pulmonary-function abnormalities overlap between entities.

Disease identification requires clinicopathologic correlation rather than a restrictive test alone.

The same advanced fibrotic appearance can obscure distinct early disease features.

Slide 7 · UIP describes a pattern; IPF describes a disease

Usual interstitial pneumonia (UIP)

Morphologic pattern of patchy interstitial scarring

Characterized by fibroblastic foci and honeycombing

May arise in several diseases

Idiopathic pulmonary fibrosis (IPF)

Clinical disease with characteristic UIP phenotype

No identified explanatory underlying disease

Requires context and exclusion of mimics

Slide 8 · UIP can occur outside IPF

UIP-pattern fibrosis

Idiopathic pulmonary fibrosis

Connective tissue disease

Chronic hypersensitivity pneumonitis

Asbestosis

A UIP pattern is not, on its own, proof of idiopathic disease.

Slide 9 · The diagnostic importance of computed tomography

The distinctive appearance of UIP on CT may make histologic confirmation unnecessary in appropriate clinical contexts.

UIP as a pattern that can often be diagnosed radiologically.

The radiologic pattern must be interpreted with clinical and exposure information.

A CT pattern cannot independently determine whether the cause is idiopathic.

Slide 10 · An idiopathic designation is an exclusionary judgment

Recognize fibrosing interstitial disease

Assess for UIP pattern

Evaluate exposures and systemic disease

Assign IPF only in appropriate context

Conceptual diagnostic reasoning; Not a formal guideline algorithm.

Interpretation is mechanistic and conceptual; Scale and timing are schematic.

Slide 11 · The central pathogenic proposition

Genetic and age-related susceptibility allows recurrent alveolar epithelial injury to trigger abnormal repair rather than architectural restoration.

Environmental factors are proposed sources of repeated epithelial damage.

Injured epithelium and responding immune cells may release profibrotic mediators.

Activated interstitial fibroblasts synthesize extracellular collagen.

Slide 12 · Environmental factors associated with IPF

Cigarette smoking is the principal environmental risk factor highlighted by Robbins.

Air pollution, microaspiration, metal fumes and wood dust are also implicated.

Some occupational associations include farming, hairdressing and stone polishing.

These associations support, but do not prove, recurrent epithelial injury as a common mechanism.

Slide 13 · Smoking is a risk amplifier, not a sufficient cause

Cigarette smoking increases IPF risk several-fold account.

Most exposed people do not develop IPF.

Risk therefore reflects an interaction between exposure and host susceptibility.

Smoking is a risk association—not a unique diagnostic marker for IPF.

Slide 14 · Inhaled irritants may repeatedly injure epithelium

Inhaled irritants or toxins

Recurrent alveolar epithelial injury

Aberrant wound-repair signaling

Progressive interstitial scarring

Hypothesized causal chain, not an experimentally proven sequence for every exposure.

Interpretation is mechanistic and conceptual; Scale and timing are schematic.

Slide 15 · Microaspiration is one proposed epithelial insult

Microaspiration among exposures associated with IPF.

The proposed common consequence is recurring alveolar epithelial damage.

Microaspiration does not by itself establish that an individual's fibrosis is idiopathic.

The pathogenic contribution in individual patients remains incompletely resolved.

Slide 16 · Why exposure alone cannot explain disease

Exposure is common

Smoking and environmental irritants affect many people

A typical exposure does not invariably lead to fibrosis

An association does not prove a sole cause

IPF is uncommon

Inherited variation can affect cellular resilience

Age alters vulnerability to injury

Additional factors are necessary for disease expression

Slide 17 · Age-related susceptibility matters

IPF rarely presents before 50 years of age in the Robbins account.

Older age may reflect loss of epithelial regenerative capacity or other acquired changes.

Age-related telomere shortening is one candidate mechanism.

The exact contribution of aging-related changes remains uncertain.

Slide 18 · Genetic susceptibility involves several pathways

Epithelial vulnerability

Telomere maintenance genes

Surfactant protein folding

MUC5B promoter variation

Age-related alterations

Established genetic associations do not imply identical mechanisms in all cases.

Slide 19 · Telomeres help preserve proliferative capacity

Telomere maintenance

Protection against premature senescence

Persistence of epithelial renewal capacity

Repair after alveolar injury

Normal-protection model; Loss of maintenance may compromise repair.

Interpretation is mechanistic and conceptual; Scale and timing are schematic.

Slide 20 · Telomere maintenance genes linked to IPF

TERT, TERC, PARN and RTEL1 are linked to telomere maintenance and IPF risk.

Defective maintenance can accelerate telomere shortening.

Short telomeres predispose epithelial cells to senescence.

A reduced capacity for epithelial replacement can increase vulnerability to repeated insults.

Slide 21 · Familial and sporadic telomere observations

Familial IPF

Inherited telomere gene defects are reported in up to 15% of familial cases.

An inherited variant helps explain susceptibility.

Not every familial case has an identified defect.

Sporadic IPF

Abnormally short lymphocyte telomeres are reported in up to 25% of cases.

This is an association rather than proof of causation in each patient.

The measures and patient groups are not directly interchangeable.

Slide 22 · Cellular senescence links telomeres to failed repair

Impaired telomere maintenance

Telomere attrition

Premature epithelial senescence

Diminished regenerative response

Schematic interpretation of the telomere-senescence hypothesis.

Interpretation is mechanistic and conceptual; Scale and timing are schematic.

Slide 23 · Surfactant gene variants affect type II pneumocytes

Rare familial IPF forms involve genes encoding components of surfactant.

Mutant surfactant proteins can fold abnormally.

Misfolded protein burden triggers the unfolded protein response.

The stressed type II pneumocyte becomes more sensitive to environmental injury.

Slide 24 · Unfolded protein response: Cellular stress model

Abnormally folded surfactant protein

Unfolded protein response

Type II pneumocyte dysfunction

Greater vulnerability to insults

Mechanism described for certain rare inherited IPF-associated variants.

Interpretation is mechanistic and conceptual; Scale and timing are schematic.

Slide 25 · MUC5B promoter variation is strongly associated

A promoter polymorphism affecting MUC5B is reported in roughly one-third of IPF cases.

The variant increases production of the mucin MUC5B.

Altered mucociliary clearance is a possible mechanistic consequence.

Exactly how increased MUC5B influences IPF risk remains uncertain.

Slide 26 · Genetic association does not establish mechanism

What is supported

MUC5B promoter polymorphism associates with IPF.

MUC5B secretion increases.

Telomere-related defects and surfactant variants are implicated.

What remains unresolved

Whether altered clearance mediates MUC5B-associated risk

Precise molecular linkage from epithelial injury to fibrosis

How different susceptibility pathways interact

Slide 27 · A convergent model of epithelial vulnerability

Recurrent epithelial damage

Environmental exposures

Genetic susceptibility

Age-related change

Abnormal repair responses

Multiple inputs converge on persistent injury rather than constituting alternative diagnoses.

Slide 28 · Injured alveolar epithelium is the proposed initiator

Alveolar epithelial injury is prominent in proposed models of IPF pathogenesis.

The initiating injury is often recurrent or persistent rather than a single discrete event.

An abnormal healing program favors collagen deposition over restoration of thin alveolar septa.

Precisely how epithelial injury is converted into fibrogenesis remains unknown.

Slide 29 · Epithelial profibrotic signaling model

Alveolar epithelial injury

Epithelial mediator release

TGF-β–associated fibroblast activation

Collagen deposition

One proposed mechanistic model; Mediators and relationships are not fully established.

Interpretation is mechanistic and conceptual; Scale and timing are schematic.

Slide 30 · Immune responses may amplify fibrogenesis

Epithelial damage signals

Innate and adaptive immune response

Profibrotic mediator production

Activated fibroblasts

Second proposed model; It is not mutually exclusive with epithelial signaling.

Interpretation is mechanistic and conceptual; Scale and timing are schematic.

Slide 31 · The epithelial and immune models can coexist

Epithelial-origin model

Damaged epithelial cells release fibrogenic signals

TGF-β is a candidate mediator

Directs abnormal fibroblast activation

Immune-amplification model

Danger signals recruit immune responses

Immune cells may supply additional profibrotic mediators

Amplifies and sustains local tissue repair signaling

Slide 32 · Fibroblasts are the collagen-producing effectors

Profibrotic microenvironment

Interstitial fibroblast activation

Extracellular collagen deposition

Septal thickening and distortion

Links cellular activation to the defining scar-forming tissue response.

Interpretation is mechanistic and conceptual; Scale and timing are schematic.

Slide 33 · PI3K–AKT signaling: Suggestive, not proven causal

Altered PI3 kinase signaling has been described in IPF-associated fibroblasts.

Increased PI3K/AKT signaling is included' mechanistic model.

Observed signaling changes may accompany aberrant fibroblast activation.

A direct causal link between these changes and progressive fibrosis has not been established.

Slide 34 · Fibrosis changes architecture and mechanics

Repeated collagen accumulation

Loss of delicate alveolar network

Stiffer lung parenchyma

Impaired ventilation and gas exchange

Pathology-to-physiology sequence based on the described interstitial scarring.

Interpretation is mechanistic and conceptual; Scale and timing are schematic.

Slide 35 · Mechanisms: Supported elements and open questions

Better established

Recurrent epithelial injury / vulnerability

Collagen-producing activated fibroblasts

Fibrotic architectural distortion

Genetic risk associations

Incomplete or hypothetical

Exact molecular initiating injury

Dominant cellular source of profibrotic mediators

Causal status of PI3K/AKT abnormalities

MUC5B-to-fibrosis link

Slide 36 · Gross disease favors peripheral and lower lung

Subpleural + lower-lobe predominance (schematic)

Lower-lung emphasis

Morphologic interpretation

Fibrosis preferentially affects lower lobes.

Subpleural regions are emphasized.

Scarring also tracks interlobular septa.

Slide 37 · Pleural cobblestoning is produced by scar retraction

Septal and subpleural fibrosis

Contraction of fibrous scars

Pleural surface puckering

Cobblestoned gross appearance

Anatomic mechanism of the textbook gross finding.

Interpretation is mechanistic and conceptual; Scale and timing are schematic.

Slide 38 · The cut lung becomes firm and rubbery

Grossly, fibrotic areas are firm, rubbery and white on the cut surface.

Dense matrix deposition replaces normal compliant parenchyma.

The distribution is patchy rather than entirely uniform.

Subpleural, septal and lower-lobe accentuation is characteristic of the description.

Slide 39 · UIP histology is defined by heterogeneity

Relatively preserved

Scarred lung

Schematic architecture — not a histology image.

Morphologic interpretation

Normal or near-normal lung neighbors severely scarred areas.

Lesions vary in location and severity.

This unequal geographic distribution is spatial heterogeneity.

Slide 40 · Spatial heterogeneity: Two regions, one specimen

Relatively preserved region

Open alveoli and thinner septa

More recognizable pulmonary architecture

Low-power comparison is essential

Advanced fibrotic region

Loss of normal alveolar topology

Confluent collagen deposition

Cystic honeycomb remodeling may appear

Slide 41 · Temporal heterogeneity reflects lesions of different ages

Cell-rich focus

Evolving scar

Dense old scar

Schematic stages coexist in UIP; Not a literal time series.

Morphologic interpretation

Active fibroblastic foci coexist with older dense scars.

Early lesions are more cellular.

Mature lesions are increasingly fibrotic and hypocellular.

Slide 42 · Fibroblastic foci are an early active lesion

Fibroblastic foci represent exuberant local fibroblast proliferation within the evolving lesion.

They are characteristic components of the UIP pattern.

They identify sites of active fibrotic remodeling.

Their coexistence with established scar helps demonstrate temporal heterogeneity.

Slide 43 · Early cellular lesion evolves toward dense scar

Fibroblastic proliferation

Progressive extracellular matrix production

Less cellular mature fibrosis

Architectural obliteration

Simplified morphologic progression; UIP contains multiple stages simultaneously.

Interpretation is mechanistic and conceptual; Scale and timing are schematic.

Slide 44 · Honeycomb fibrosis marks architectural destruction

Cystic spaces in scar — schematic, not microscopy.

Morphologic interpretation

Dense fibrosis destroys native alveolar architecture.

Residual cystic spaces form within remodeled fibrotic lung.

The term refers to end-stage structural remodeling, not true normal alveoli.

Slide 45 · Honeycomb spaces develop an epithelial lining

The cystic spaces can be lined by hyperplastic type II pneumocytes or bronchiolar epithelium.

Epithelial lining persists despite loss of normal alveolar structure.

Replacement-type lining differs from healthy thin gas-exchange septa.

The surrounding collagenous scar is central to identification of honeycombing.

Slide 46 · Inflammation is present but usually not dominant

UIP fibrotic areas may contain mild to moderate inflammatory infiltrates.

Lymphocytes predominate; Plasma cells and granulocytes may be admixed.

The principal defining lesion is fibrosis, not diffuse inflammatory consolidation.

Interpret the infiltrate in combination with spatial and temporal pattern.

Slide 47 · Other changes may accompany UIP fibrosis

Focal squamous metaplasia may accompany epithelial remodeling.

Smooth-muscle hyperplasia may be encountered in fibrotic regions.

Pulmonary vascular changes can include arterial intimal fibrosis and medial thickening.

These are associated findings; They do not replace the core diagnostic pattern.

Slide 48 · Pulmonary arterial remodeling accompanies advanced disease

Persistent interstitial lung injury

Vascular intimal and medial thickening

Pulmonary arterial hypertensive changes

Additional cardiopulmonary burden

Vascular morphology without requiring a specific hemodynamic cutoff.

Interpretation is mechanistic and conceptual; Scale and timing are schematic.

Slide 49 · Acute exacerbation overlays an established UIP background

Underlying chronic UIP

Patchy dense fibrosis

Fibroblastic foci and honeycombing

Spatial and temporal heterogeneity

Superimposed acute process

Diffuse alveolar damage (DAD)

Abrupt additional alveolar injury

May accompany rapid clinical deterioration

Slide 50 · Integrated histologic recognition of UIP

Preserved lung

Fibroblastic focus

Dense scar

Honeycomb change

Schematic — not histology.

Morphologic interpretation

Patchy interstitial dense fibrosis.

Normal lung beside destroyed architecture.

Fibroblastic foci alongside old scar.

Honeycomb cystic spaces in advanced areas.

Slide 51 · Adequate sampling matters in advanced fibrosis

Dense fibrosis and fibroblastic foci can remain identifiable even in advanced IPF, provided sampling is adequate.

Sampling only one fibrotic region may obscure spatial variation.

Recognizing different lesion ages requires architectural context.

Interpret an individual tissue sample within the overall clinical and radiologic phenotype.

Slide 52 · Symptoms begin insidiously

Progressive exertional dyspnea is a typical presenting complaint.

Cough is commonly dry rather than prominently productive.

Gradual onset is consistent with accumulating parenchymal fibrosis.

Many patients are between 55 and 75 years at presentation account.

Slide 53 · Stiff lung and impaired diffusion explain dyspnea

Collagen-rich thickened interstitium

Reduced compliance + impaired diffusion

Increased ventilatory effort

Progressive exertional breathlessness

Mechanistic integration of the source pathology and restrictive physiologic pattern.

Interpretation is mechanistic and conceptual; Scale and timing are schematic.

Slide 54 · Late clinical signs mark significant disease

Hypoxemia may develop as gas exchange becomes compromised.

Cyanosis and digital clubbing occur late in the described clinical course.

End-inspiratory crackles are typical of chronic interstitial lung disease.

Absence of wheezing helps distinguish the restrictive phenotype from classic obstruction.

Slide 55 · Pulmonary function reflects restriction

Expected restrictive changes

Reduced lung volumes / forced vital capacity

Reduced lung compliance

Reduced diffusion capacity

Relation to obstruction

FEV₁/FVC generally remains normal in pure restriction

The primary pathology is interstitial, not airway occlusion

Clinical overlap still requires diagnostic assessment

Slide 56 · Clinical progression varies between patients

More usual trajectory

Gradually worsening exertional dyspnea

Progressive pulmonary functional limitation

Eventually respiratory failure

Rapid deterioration

Acute exacerbation may occur

Diffuse alveolar damage can be superimposed

An individual trajectory is difficult to predict

Slide 57 · Prognosis is serious but individually unpredictable

A median survival of approximately 3.8 years after diagnosis in its source discussion.

This is a textbook population summary, not an individual prediction.

A slowly progressive course and sudden acute exacerbations can both occur.

Timing, case mix and modern management may affect estimates across cohorts.

Slide 58 · Distinguishing UIP from nonspecific interstitial pneumonia

UIP / typical IPF pattern

Temporal heterogeneity: Early foci + old scar

Fibroblastic foci and honeycombing

Typically worse prognosis

NSIP pattern

More temporally uniform lesions

Fibroblastic foci and honeycombing absent description

Often a more favorable prognosis

Slide 59 · Distinguishing UIP from organizing pneumonia

UIP pattern

Interstitial collagenous fibrosis

Distorted or destroyed lung architecture

Fibroblastic foci and honeycombing

Organizing pneumonia pattern

Loose polypoid plugs in distal airspaces (Masson bodies)

Underlying lung architecture preserved

Honeycombing and interstitial scar not defining features

Slide 60 · A UIP pattern demands assessment of alternative causes

UIP phenotype

Systemic autoimmune features

Chronic inhalational antigen exposure

Asbestos exposure history

Idiopathic disease after evaluation

These categories must be distinguished clinically, by laboratory information and sometimes histology.

Slide 61 · Therapeutic implications of a fibrosing disorder

Antifibrotic targeted therapy as slowing progression, rather than reversing established architectural loss.

One reported strategy targets tyrosine kinase signaling.

A second antifibrotic strategy is described in the source as antagonism of TGF-β signaling.

Lung transplantation is described as the only definitive therapy.

Slide 62 · Clinical case: Interpret the pattern

An older adult develops progressive exertional dyspnea and dry cough. A fibrotic lung sample has preserved airspaces adjacent to dense scar, fibroblastic foci and honeycomb remodeling.

What histologic pattern is being described?

Instructor answer and interpretive rationale are in speaker notes.

Slide 63 · Clinical case: Do not equate UIP with IPF

A patient with a systemic autoimmune disease has a lung biopsy showing patchy dense fibrosis, fibroblastic foci and honeycomb cysts.

Can this be labeled IPF solely from histology?

Instructor answer and interpretive rationale are in speaker notes.

Slide 64 · Morphology case: Spatial versus temporal heterogeneity

In one resection, a relatively normal region lies next to dense scar. Elsewhere a cellular fibroblastic focus lies alongside old acellular fibrosis.

Identify the two different heterogeneities.

Instructor answer and interpretive rationale are in speaker notes.

Slide 65 · Integrated diagnostic reasoning

Fibrosing restrictive clinical syndrome

Radiologic / morphologic UIP phenotype

Consider other UIP-producing diseases

IPF when idiopathic context is appropriate

Conceptual synthesis; Not a substitute for a validated practice guideline.

Interpretation is mechanistic and conceptual; Scale and timing are schematic.

Slide 66 · The essential morphologic signature

UIP combines a patchwork of old and active fibrosis with destruction of the normal alveolar scaffold.

Spatial heterogeneity: Relatively preserved lung beside dense scar.

Temporal heterogeneity: Fibroblastic foci beside mature fibrosis.

Honeycomb fibrosis: Cystic remodeled spaces within destroyed architecture.

These patterns require correlation before diagnosing idiopathic disease.

Slide 67 · Five points to retain

IPF is a progressive clinical disorder; UIP is its characteristic, nonexclusive morphologic pattern.

Recurrent epithelial injury interacts with aging and genetic susceptibility.

Activated fibroblasts deposit collagen; mechanistic details remain incompletely established.

Patchy fibrosis, fibroblastic foci and honeycombing are the diagnostic morphologic triad.

Restrictive physiology and variable progression follow architectural remodeling.